Eli Lilly Sues Six Retatrutide Sellers | What the August 2026 Filings Mean for Peptide Companies, Clinics, and Compounding Pharmacies

On August 12, 2026, Eli Lilly and Company filed six lawsuits over products sold as retatrutide. Five defendants are in Texas and one is in California. One is a licensed compounding pharmacy. One is an aesthetics clinic. The rest are peptide vendors. In the same announcement, Lilly disclosed something that matters more than the lawsuits: it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement, and professional licensing boards, and reported more than 14,000 websites, advertisements, social media posts, and product listings across more than 100 countries. If you sell, compound, or administer peptides, read that second sentence twice. The lawsuits are the visible part. The referral program is the part that puts people in a room with a federal agent.

Six federal complaints filed August 12, 2026. More than 200 referrals to FDA, DOJ, state attorneys general, and licensing boards disclosed in the same announcement.

Key Takeaways

• Eli Lilly filed six lawsuits on August 12, 2026 over retatrutide products labeled for research use but sold for human use.
• Lilly reported referring more than 200 individuals and entities to FDA, DOJ, state attorneys general, and professional licensing boards.
• Retatrutide cannot be lawfully compounded. It has no monograph and appears on neither the 503A nor the 503B bulks list.
• Selling an unapproved new drug violates 21 U.S.C. § 331(d) and § 355(a), with felony exposure under § 333(a)(2).
• Florida sellers face a parallel second-degree felony under Fla. Stat. § 499.0051, chargeable in state court without any federal case.

What Lilly Filed, and Against Whom

Per Lilly, the six defendants and courts are Aesthetic Envy Cosmetic Centers LLC in the Northern District of California, Astra LLC doing business as Astra Peptides in the Western District of Texas, Legendary Peptides, LLC in the Eastern District of Texas, Striker Pharmacy, LLC in the Southern District of Texas, Texas Peptides Inc. in the Western District of Texas, and Lone Star Peptide Co. in the Southern District of Texas.

Lilly alleges the defendants marketed the products for research use only while selling them for human use. Lilly also called on credit card companies, payment processors, and shipping and logistics companies to cut off the businesses that move this product.

"Entirely unverified, unapproved and not worth the risk."— Dr. David Hyman, Chief Medical Officer, Eli Lilly and Company, describing products sold as retatrutide

These are allegations and no defendant has been found liable. What matters for everyone else in this industry is the target set. Lilly did not limit itself to online vendors. It sued a licensed pharmacy and a clinic in the same wave.

Why Retatrutide Leaves a Seller With No Regulatory Defense

The tirzepatide and semaglutide cases gave compounders something to argue about. Shortage status, patient-specific need, whether a formulation was essentially a copy. Retatrutide gives them nothing. It has never been approved by FDA for any indication and has never been in shortage. FDA said so in a March 31, 2025 letter to the National Association of Boards of Pharmacy. Retatrutide has no USP or NF monograph, is not a component of any FDA-approved drug, and appears on neither the 503A bulks list nor the 503B bulks list.

FDA has repeatedly pointed to the bacteriostatic water sold alongside the peptide as proof of intended human use. The disclaimer on the vial does not survive the rest of the record.

Under 21 U.S.C. § 353a, a bulk substance qualifies for compounding only through a monograph, status as a component of an approved drug, or the bulks list. Retatrutide satisfies none of the three, and § 353b offers no shortage pathway because there is no approved product to be in shortage of. FDA has stated this directly in warning letters, including one to GLP-1 Solution on September 9, 2025 and one to Gram Peptides on March 31, 2026.

The Referral Pipeline, and Why It Changes the Risk Profile

A warning letter invites correction. A private plaintiff seeks disgorgement and fees. A referral to FDA Office of Criminal Investigations or the Department of Justice is a third thing, and it does not come with a letter telling you it happened.

Public enforcement was already moving before Lilly filed. FDA issued six warning letters to peptide sellers on March 31, 2026, three of them to Florida businesses, another on June 17, 2026, and warned 30 telehealth companies on March 3, 2026.

The referral does not depend on a lawsuit, and the absence of a warning letter is not evidence that nobody is looking. Assume any business with a public storefront that has listed retatrutide is already in a referral file.

The criminal side is further along than most operators realize. On July 30, 2026, a peptide seller in the Northern District of Indiana was sentenced to 70 months in prison with a $5,000,000 money judgment after selling to roughly 54,000 customers in all fifty states. In April 2026, a licensed osteopathic physician was indicted in the District of Utah for obtaining peptides from China and reselling them to more than 200 patients under his own labels.

Exposure: The Statutes That Apply

A peptide becomes a drug under 21 U.S.C. § 321(g)(1) the moment the seller intends it for human use. Intended use is determined from the whole record, not from the label. FDA amended its intended use rule at 86 Fed. Reg. 41383 and stated plainly that a self-serving disclaimer cannot mask a vendor's true intent. In the March 2026 warning letters FDA pointed to dosing schedules, clinical trial percentages, indication lists, and the sale of bacteriostatic water alongside the peptide.

• Unapproved new drug. 21 U.S.C. § 355(a) and § 331(d).
• Misbranding. 21 U.S.C. § 352(f)(1), lack of adequate directions for use.
• Criminal penalties. 21 U.S.C. § 333(a)(1) is a strict liability misdemeanor. Section 333(a)(2) is a three-year felony where the government proves intent to defraud or mislead.
• Fraud and conspiracy. 18 U.S.C. § 1343 wire fraud and § 371 conspiracy routinely accompany the FDCA counts.
• Florida. Fla. Stat. § 499.005 prohibits selling or delivering a misbranded or adulterated drug. Section 499.0051 makes that a second-degree felony, and operating without a prescription drug wholesale distributor permit a third-degree felony.

That Florida chapter is the one most operators and their counsel overlook. A state prosecutor in Palm Beach or Broward County can charge a peptide seller with no federal involvement at all.

Mistakes People Make in the First Thirty Days

1. Talking to an agent at the door. FDA Office of Criminal Investigations agents are federal agents. A false or careless statement is a separate five-year felony under 18 U.S.C. § 1001. There is no version of that conversation that helps.
2. Purging the website and the social accounts. This is the reflex and the worst possible move. It is spoliation in the civil case and consciousness of guilt in the criminal one. Preserve everything, including the posts you regret.
3. Answering the civil complaint without criminal counsel involved. A corporation has no Fifth Amendment privilege. Individual principals do, and it is easy to waive it in a civil deposition.
4. Signing a consent judgment to make the case go away. A consent judgment or injunction becomes the government's exhibit on willfulness, which is what converts a misdemeanor into a felony under § 333(a)(2).
5. Waiting for charges. By the time an indictment issues, the charging decision has been made. Federal investigation defense is most effective before that point, not after.

How a Defense Is Built at This Stage

Parallel-track the matter from day one. The civil case and the criminal exposure are one problem. Sequencing discovery, deciding who sits for a deposition, and deciding whether to assert the Fifth are strategic choices with criminal consequences.

On the merits, intent is the battleground. The Department of Justice has been charging intent-based felonies in this space rather than strict liability misdemeanors, which means knowledge and intent stay contestable. McFadden v. United States, 576 U.S. 186 (2015), supports the position that the government must prove actual subjective knowledge and not merely that a disclaimer was legally insufficient.

On the civil side, the productive defense so far has been Lanham Act proximate causation under Lexmark International, Inc. v. Static Control Components, Inc., 572 U.S. 118 (2014). Because a prescriber sits between the advertisement and the purchase, plaintiffs have struggled to trace lost sales, and federal courts have dismissed § 1125(a) counts on that ground.

Why the Next Few Weeks Matter

Charging decisions in these cases stay fluid for a long time. Prosecutors weigh volume, customer harm, foreign sourcing, and how the operator behaved once he knew. That last factor is the only one still within a client's control, and it disappears the moment someone deletes a page or answers a question at the door.

Florida is exposed here for a specific reason. Three of the six FDA warning letters in March went to Florida businesses, the state has an independent felony statute in Chapter 499, and the Southern District of Florida has one of the most active healthcare and pharmaceutical enforcement dockets in the country. A peptide operation run out of Boca Raton, Fort Lauderdale, or Miami is sitting in the middle of that.

Common Questions

Under Investigation Over Peptide or Compounded Drug Sales?

AMC Defense Law is a federal criminal defense and white collar defense firm representing businesses, pharmacies, clinics, and licensed professionals in investigations and prosecutions involving unapproved drugs, misbranding, and compounded products. If you have received an FDA warning letter, a civil complaint from a manufacturer, a federal grand jury subpoena, or a target letter, the early decisions carry the most weight. Consultations are confidential. Call 561-542-5494 or contact the firm to discuss your situation privately.

The civil complaint and the criminal exposure are one problem. AMC Defense Law parallel-tracks both from the first week, before the charging decision hardens.

If you or your loved ones have been arrested or contacted by federal investigators over peptide or compounded drug sales, call Aaron M. Cohen for a confidential consultation, 24 hours a day, to get help.

This article is provided for general informational purposes only and does not constitute legal advice. Reading it does not create an attorney-client relationship with AMC Defense Law or any of its attorneys. The lawsuits described are allegations only and no defendant has been found liable. Legal outcomes depend on the specific facts and circumstances of each matter, and no result is guaranteed. Regulatory requirements in this area are changing. Consult a licensed attorney about your particular situation before acting on any information contained here.

About the author: Aaron M. Cohen is the founder of AMC Defense Law, a federal and state criminal defense firm in Boca Raton, Florida. He is admitted to practice in New York and Florida and before the United States District Courts for the Southern District of New York and the Southern District of Florida. Florida Bar No. 541427. The firm represents clients in federal investigations and prosecutions involving healthcare fraud, Anti-Kickback Statute matters, peptide and compounded drug enforcement, controlled substances, financial crimes, and complex federal litigation, in Florida and nationwide.